Journal Home
Search for

Volume 51, Issue 4, Pages 671-677 (April 2008)


View previous. 26 of 321 View next.

Complement Factor H Deficiency and Posttransplantation Glomerulonephritis With Isolated C3 Deposits

Olivia Boyer, MD1, Laure-Hélène Noël, MD, PhD2, Eve Balzamo, MD1, Geneviève Guest, MD1, Nathalie Biebuyck, MD1, Marina Charbit, MD, PhD1, Rémi Salomon, MD, PhD1, Véronique Frémeaux-Bacchi, MD, PhD3, Patrick Niaudet, MD1Corresponding Author Informationemail address

Received 12 July 2007; accepted 19 November 2007.

We report the first cases of atypical hemolytic and uremic syndrome associated with complement factor H (CFH) deficiency in native kidneys and glomerulonephritis with isolated C3 deposits after kidney transplantation. Two boys developed atypical hemolytic and uremic syndrome at 16 and 11 months of age, associated with low C3 and CFH levels. Both rapidly progressed to end-stage renal failure and received a kidney transplant. Patient 1 had combined CFH and complement factor I (CFI) heterozygous mutations and a membrane cofactor protein (gene symbol, CD46) gene polymorphism. Five years posttransplantation, an allograft biopsy specimen showed numerous mesangial and extramembranous C3 deposits, although the patient had no biological sign of glomerulopathy. Nine years after transplantation, he was well with stable kidney function. Patient 2, who had a homozygous CFH mutation, developed glomerulonephritis with isolated C3 deposits 5 months after kidney transplantation while he was treated for early recurrence of hemolytic anemia. Four years later, the second kidney transplant biopsy specimen showed recurrence of thrombotic microangiopathy. Six years posttransplantation, kidney function was stable and complete blood cell count was normal with regular plasma therapy. These observations suggest that constitutional dysregulation of the alternative pathway is associated with a wide spectrum of kidney diseases, and glomerulonephritis with isolated C3 deposits and thrombotic microangiopathy may be different expressions of the same condition. Several factors could influence the disease, such as degree of CFH haploinsufficiency and other complement alternative pathway regulator abnormalities, such as a membrane cofactor protein polymorphism.

1 Pediatric Nephrology, Hôpital Necker Enfants Malades, Université Paris Descartes, Paris, France

2 INSERM U845, Hôpital Necker Enfants Malades, Université Paris Descartes, Paris, France

3 Assitance Publique Hopitaux de Paris, Laboratory of Immunology, Hôpital Européen Georges Pompidou, Université Paris Descartes, Paris, France.

Corresponding Author InformationAddress correspondence to Patrick Niaudet, MD, Service de Néphrologie Pédiatrique, Hôpital Necker Enfants Malades, 149 rue de Sèvres, 75743 Paris cedex 15, France.

PII: S0272-6386(08)00040-1

doi:10.1053/j.ajkd.2007.11.032


View previous. 26 of 321 View next.